Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Eli Lilly ( LLY -1.63%) and Microsoft ( MSFT 1.20%) are two high-flying dividend stocks in the S&P 500 index. Here's why the ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Conditions are getting a bit more challenging for the drugmaker.

The UAlbany women's basketball team beats Rhode Island Friday in a nonconference game featuring a matchup of twin sisters.

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...

TD Cowen analyst Joseph Thome has maintained their bullish stance on ANAB stock, giving a Buy rating today. Joseph Thome’s rating is ...